C12N 2820/00
Vectors comprising a special origin of replication system
C12N2820/00 (Vectors comprising a special origin of replication system) appears on 158 US grants and 327 published applications in this corpus.
Search patents in C12N- Granted patents
- 158
- Published applications
- 327
- Assignees
- 181
- Inventors
- 622
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 1 |
| 2003 | 1 | 7 |
| 2004 | 1 | 1 |
| 2005 | 0 | 3 |
| 2006 | 1 | 5 |
| 2007 | 1 | 6 |
| 2008 | 2 | 12 |
| 2009 | 2 | 6 |
| 2010 | 5 | 11 |
| 2011 | 2 | 12 |
| 2012 | 5 | 7 |
| 2013 | 5 | 9 |
| 2014 | 6 | 10 |
| 2015 | 4 | 12 |
| 2016 | 10 | 14 |
| 2017 | 10 | 20 |
| 2018 | 9 | 11 |
| 2019 | 13 | 22 |
| 2020 | 7 | 19 |
| 2021 | 4 | 14 |
| 2022 | 4 | 24 |
| 2023 | 24 | 26 |
| 2024 | 16 | 22 |
| 2025 | 11 | 38 |
| 2026 | 8 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2820/60From virusesIndexing code72
- C12N 2820/55From bacteriaIndexing code48
- C12N 2820/002Inducible or controllableIndexing code28
- C12N 2820/007Tissue or cell-specificIndexing code21
- C12N 2820/80From vertebratesIndexing code11
- C12N 2820/10Multiple origins of replicationIndexing code9
- C12N 2820/70From fungiIndexing code4
- C12N 2820/005Cell-cycle regulatedIndexing code2
All 10 subgroupsShow fewer
Recent patents
- Enumeration of genetically engineered microorganisms by live cell counting techniques1 Sep 2026US 12,721,882 B2Synlogic Operating Company, Inc.
- Mammalian cells comprising integrated CAS9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites4 Aug 2026US 12,698,514 B2Regeneron Pharmaceuticals, Inc.
- Mammalian expression vectors30 Jun 2026US 12,668,809 B2Biocon Biologics Limited
- SmartBac baculovirus expression system and application thereof9 Jun 2026US 12,649,931 B2Institute of Biophysics, Chinese Pie Academy of Sciences
- DNA vectors and elements for sustained gene expression in eukaryotic cells28 Apr 2026US 12,612,646 B2Dna Twopointo Inc.
- Artificial martellivirales satellite rnas1 Oct 2026US 2026/0297605 A1Flagship Pioneering Innovations Vii, LLC
- Viral and non-viral nanoplasmid vectors with improved production24 Sep 2026US 2026/0286384 A1Aldevron, LLC
- Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites10 Sep 2026US 2026/0265784 A1Regeneron Pharmaceuticals, Inc.
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
- Components for genomic editing13 Aug 2026US 2026/0234657 A1Kano Therapeutics Inc.
Most cited
By later US patents
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017
- Vectors for tissue-specific replication124US 5,998,205 AGenetic Therapy, Inc. · 1999
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Modified transposon vector and its use106US 9,175,295 B2The Chemo-Sero-Therapeutic Research Institute · 2015
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002